We’ve had three interesting health care papers produced at CAP over the past couple of days that I wanted to highlight. First, David Balto writes about the possibility of using anti-trust laws to eliminate barriers to generic drug competition:
Stopping these types of anticompetitive conduct could not be a greater priority for the Obama administration’s antitrust enforcers. With more than $60 billion in drugs scheduled to go “off patent” during the remainder of the President’s first term, stopping anticompetitive conduct in the pharmaceutical industry is crucial to controlling health care costs. If antitrust is a “consumer welfare prescription,” then our health care system is certainly in need of a prescription for an added dose of enforcement in pharmaceutical markets.
Next, David Cutler and Melinda Beeuwkes Buntin write about saving over $1 trillion by reforming health care.
And last, Ellen-Marie Whelan and Judy Feder on transforming the health payment system so that we pay providers to make people healthier rather than just paying them to do stuff.